Boston Scientific Reports Record Q1 2026 Earnings with $5.2B Revenue and 99% Profit Surge Driven by Cardiovascular and Electrophysiology Innovations

Significant Profit Surge in Q1 2026

Double-digit growth in cardiovascular business

By sector,Cardiovascular Division Sales Reach $3.503 Billion, Reporting a 13.5% Growth, operations and organic growth of 11.2%.

Medical SurgeryDepartment sales reached $1.701 billion, reporting a 7.8% increase, operations and organic growth of 5.7%. Among them, endoscopy revenue was $736 million, an increase of 9.4%;Urology revenue was $646 million, an increase of 2.1%;Neuromodulation revenue amounted to $318 million, representing a 17.4% increase.

In the field of urology, Boston Scientific completed its acquisition of Valencia Technologies Corporation in April this year. The latter is a company that develops solutions for treating bladder dysfunction.'s company, itsThe core product eCoin Implantable Tibial Nerve Stimulation (ITNS) device canTreatment of urge urinary incontinence. This is also currentlyA High-Growth New Niche in the Urology Market.

By region, the U.S. market reported a 10.9% growth, while Europe, the Middle East, and Africa reported a 10.1% growth,The Asia-Pacific region reported a 14.7% increase, while Latin America and Canada reported a 19.0% increase.

At the board level, Starbucks Chief Financial OfficerCathy Smith, President and Chief Executive Officer of Takeda Pharmaceutical CompanyChristophe Weber，Elected to the Board of Directors of Boston Scientific.

As of the market close on that day,Boston Scientific Stock Price Rises8.99%, reported at $64.870.

Results of Multiple Clinical Trials Released

These areas are progressing smoothly.

Over time, Boston Scientific has released results from multiple clinical trials, confirming the favorable clinical performance of its related products.

As a key driver of performance growth, the latest advancements in electrophysiology have garnered significant attention.

Recently, Boston Scientific announced positive results from the ADVENT long-term outcomes clinical trial, which demonstrated thatCompared with thermal ablation, FARAPULSE™ pulsed field ablation demonstrates superior performance at four years in terms of atrial fibrillation treatment success rate, reduction in in-hospital arrhythmia interventions, and lower repeat ablation rates.。

In the first quarter of this year, Boston ScientificThe company’s new OPAL HDx™ 3D cardiac electrophysiology mapping system has officially received approval from the National Medical Products Administration. Equipped with the FARAVIEW™ software module, the system can be used in conjunction with the FARAWAVE™ NAV disposable magnetically localized cardiac pulsed field ablation catheter, which features added magnetic localization capabilities, to enable 3D cardiac mapping.

Data shows that,2025The global market size for pulsed electric field ablation has exceeded55billion USD, compared to2024Year-on-Year Growth35%. In the coming years, the revolutionary impact of this field on the electrophysiology market will become even more apparent.

Since its product approval, Boston Scientific has gradually established a significant advantage in the field of pulsed field ablation (PFA). However, medical device giants such as Medtronic, Abbott, and Johnson & Johnson are also heavily investing in this sector, suggesting that the competition in the next phase of industry development will be intense.

In the field of left atrial appendage occlusion, Boston Scientific has also obtained new clinical evidence of efficacy.

In a study evaluating the WATCHMAN FLX™ left atrial appendage closure device as the preferred option for reducing stroke risk, the study met all primary and secondary endpoints.and demonstrated that the WATCHMAN FLX device is superior to oral anticoagulants in reducing bleeding risk, with similar efficacy, in a broad population of patients with non-valvular atrial fibrillation (AF)。

Furthermore, the HI-PEITHO clinical trial evaluated the EKOS™ Endovascular System for the treatment of acute pulmonary embolism (PE) in patients with intermediate-risk PE, demonstrating that the EKOS System combined with anticoagulation therapy was superior to anticoagulation therapy alone.

Results from the 24-month COMFORT clinical trial were released, demonstrating that peripheral nerve stimulation using the Nalu Neurostimulation System provides durable, statistically significant pain relief for patients with chronic pain, compared to conventional medical management.ImprovementQuality of Life.

END